JW PHARMACEUTICAL
KOSPI
₩26,600.00
-0.56%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Moderate debt: debt-to-equity of 0.64.
- Comfortable interest cover: operating profit covers interest about 10.7 times.
- Return on equity is healthy at 16.7%.
- Return on capital employed is healthy at 23.9%.
- Net profit margin is 7.9%.
- Pays a dividend (yield about 2.1%).
- Has paid a dividend in each of the last 5 years on record.
!Watch-points
No notable watch-points flagged by the automated checks.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreGrey zone
2.47
This middle range was less conclusive in Altman’s study — neither clearly safe nor clearly distressed.
Computed without the market-value term.
Piotroski F-ScoreWeak
3 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩6,088억
Current Price₩ 26,600.00
High / Low₩ 39,250.00 / 20,700.00
Stock P/E10.50
Book Value₩ 16,380.38
Dividend Yield2.10%
ROCE23.85%
ROE16.65%
Debt to Equity0.64
Current Ratio1.42
EPS₩ 2,534.00
PAT Margin7.93%
ICR10.70
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity